|
1
|
Gregory S: Adult Acute Lymphoblastic
Leukemia: Treatment and Management Updates. Semin Oncol Nurs.
35(150951)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gökbuget N, Dombret H, Ribera JM, Fielding
AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, et
al: International reference analysis of outcomes in adults with
B-precursor Ph-negative relapsed/refractory acute lymphoblastic
leukemia. Haematologica. 101:1524–1533. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Konopleva MY and Jordan CT: Leukemia stem
cells and microenvironment: Biology and therapeutic targeting. J
Clin Oncol. 29:591–599. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Witkowski MT, Kousteni S and Aifantis I:
Mapping and targeting of the leukemic microenvironment. J Exp Med.
217(217)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shafat MS, Gnaneswaran B, Bowles KM and
Rushworth SA: The bone marrow microenvironment - Home of the
leukemic blasts. Blood Rev. 31:277–286. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kumagai M, Manabe A, Pui CH, Behm FG,
Raimondi SC, Hancock ML, Mahmoud H, Crist WM and Campana D:
Stroma-supported culture in childhood B-lineage acute lymphoblastic
leukemia cells predicts treatment outcome. J Clin Invest.
97:755–760. 1996.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Manabe A, Coustan-Smith E, Behm FG,
Raimondi SC and Campana D: Bone marrow-derived stromal cells
prevent apoptotic cell death in B-lineage acute lymphoblastic
leukemia. Blood. 79:2370–2377. 1992.PubMed/NCBI
|
|
8
|
Mudry RE, Fortney JE, York T, Hall BM and
Gibson LF: Stromal cells regulate survival of B-lineage leukemic
cells during chemotherapy. Blood. 96:1926–1932. 2000.PubMed/NCBI
|
|
9
|
Shishido S, Bönig H and Kim YM: Role of
integrin alpha4 in drug resistance of leukemia. Front Oncol.
4(99)2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Damiano JS, Hazlehurst LA and Dalton WS:
Cell adhesion-mediated drug resistance (CAM-DR) protects the K562
chronic myelogenous leukemia cell line from apoptosis induced by
BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation.
Leukemia. 15:1232–1239. 2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Konopleva M, Tabe Y, Zeng Z and Andreeff
M: Therapeutic targeting of microenvironmental interactions in
leukemia: mechanisms and approaches. Drug Resist Updat. 12:103–113.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sison EAR, Kurre P and Kim YM:
Understanding the bone marrow microenvironment in hematologic
malignancies: A focus on chemokine, integrin, and extracellular
vesicle signaling. Pediatr Hematol Oncol. 34:365–378.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Guo W and Giancotti FG: Integrin
signalling during tumour progression. Nat Rev Mol Cell Biol.
5:816–826. 2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Qian H, Georges-Labouesse E, Nyström A,
Domogatskaya A, Tryggvason K, Jacobsen SE and Ekblom M: Distinct
roles of integrins alpha6 and alpha4 in homing of fetal liver
hematopoietic stem and progenitor cells. Blood. 110:2399–2407.
2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Scott LM, Priestley GV and Papayannopoulou
T: Deletion of alpha4 integrins from adult hematopoietic cells
reveals roles in homeostasis, regeneration, and homing. Mol Cell
Biol. 23:9349–9360. 2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Härzschel A, Zucchetto A, Gattei V and
Hartmann TN: VLA-4 Expression and Activation in B Cell
Malignancies: Functional and Clinical Aspects. Int J Mol Sci.
21(21)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jacamo R, Chen Y, Wang Z, Ma W, Zhang M,
Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, et al:
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of
NF-κB mediates chemoresistance. Blood. 123:2691–2702.
2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Matsunaga T, Fukai F, Miura S, Nakane Y,
Owaki T, Kodama H, Tanaka M, Nagaya T, Takimoto R, Takayama T, et
al: Combination therapy of an anticancer drug with the FNIII14
peptide of fibronectin effectively overcomes cell adhesion-mediated
drug resistance of acute myelogenous leukemia. Leukemia.
22:353–360. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hsieh YT, Gang EJ, Geng H, Park E, Huantes
S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, et al:
Integrin alpha4 blockade sensitizes drug resistant pre-B acute
lymphoblastic leukemia to chemotherapy. Blood. 121:1814–1818.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hsieh YT, Gang EJ, Shishido SN, Kim HN,
Pham J, Khazal S, Osborne A, Esguerra ZA, Kwok E, Jang J, et al:
Effects of the small-molecule inhibitor of integrin α4, TBC3486, on
pre-B-ALL cells. Leukemia. 28:2101–2104. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Vanderslice P, Biediger RJ, Woodside DG,
Berens KL, Holland GW and Dixon RA: Development of cell adhesion
molecule antagonists as therapeutics for asthma and COPD. Pulm
Pharmacol Ther. 17:1–10. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vanderslice P and Woodside DG: Integrin
antagonists as therapeutics for inflammatory diseases. Expert Opin
Investig Drugs. 15:1235–1255. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen
C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, et al:
Small-molecule inhibition of CBP/catenin interactions eliminates
drug-resistant clones in acute lymphoblastic leukemia. Oncogene.
33:2169–2178. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Adam E, Kim HN, Gang EJ, Schnair C, Lee S,
Lee S, Khazal S, Kosoyan O, Konopleva M, Parekh C, et al: The PI3Kδ
Inhibitor Idelalisib Inhibits Homing in an in Vitro and
in Vivo Model of B ALL. Cancers (Basel). 9(9)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gang EJ, Kim HN, Hsieh YT, Ruan Y, Ogana
HA, Lee S, Pham J, Geng H, Park E, Klemm L, et al: Integrin α6
mediates the drug resistance of acute lymphoblastic B-cell
leukemia. Blood. 136:210–223. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chigaev A, Wu Y, Williams DB, Smagley Y
and Sklar LA: Discovery of very late antigen-4 (VLA-4, alpha4beta1
integrin) allosteric antagonists. J Biol Chem. 286:5455–5463.
2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tissino E, Benedetti D, Herman SEM, Ten
Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben
R, et al: Functional and clinical relevance of VLA-4 (CD49d/CD29)
in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med.
215:681–697. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liang M, Schwickart M, Schneider AK,
Vainshtein I, Del Nagro C, Standifer N and Roskos LK: Receptor
occupancy assessment by flow cytometry as a pharmacodynamic
biomarker in biopharmaceutical development. Cytometry B Clin Cytom.
90:117–127. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Botta C, Cucè M, Pitari MR, Caracciolo D,
Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME,
Prabhala R, et al: MiR-29b antagonizes the pro-inflammatory
tumor-promoting activity of multiple myeloma-educated dendritic
cells. Leukemia. 32:1003–1015. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chigaev A, Waller A, Amit O, Halip L,
Bologa CG and Sklar LA: Real-time analysis of
conformation-sensitive antibody binding provides new insights into
integrin conformational regulation. J Biol Chem. 284:14337–14346.
2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Alachkar H, Santhanam R, Maharry K,
Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey
C, Neviani P, et al: SPARC promotes leukemic cell growth and
predicts acute myeloid leukemia outcome. J Clin Invest.
124:1512–1524. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Matsunaga T, Takemoto N, Sato T, Takimoto
R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, et
al: Interaction between leukemic-cell VLA-4 and stromal fibronectin
is a decisive factor for minimal residual disease of acute
myelogenous leukemia. Nat Med. 9:1158–1165. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y,
McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, et
al: Activation of integrin-linked kinase is a critical prosurvival
pathway induced in leukemic cells by bone marrow-derived stromal
cells. Cancer Res. 67:684–694. 2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Léger OJ, Yednock TA, Tanner L, Horner HC,
Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC and Bendig MM:
Humanization of a mouse antibody against human alpha-4 integrin: A
potential therapeutic for the treatment of multiple sclerosis. Hum
Antibodies. 8:3–16. 1997.PubMed/NCBI
|
|
36
|
Kent SJ, Karlik SJ, Cannon C, Hines DK,
Yednock TA, Fritz LC and Horner HC: A monoclonal antibody to alpha
4 integrin suppresses and reverses active experimental allergic
encephalomyelitis. J Neuroimmunol. 58:1–10. 1995.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ransohoff RM: Natalizumab and PML. Nat
Neurosci. 8(1275)2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Miller DH, Khan OA, Sheremata WA,
Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM,
Miszkiel KA and O'Connor PW: International Natalizumab Multiple
Sclerosis Trial Group. A controlled trial of natalizumab for
relapsing multiple sclerosis. N Engl J Med. 348:15–23.
2003.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ghosh S, Goldin E, Gordon FH, Malchow HA,
Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T and
Donoghue S: Natalizumab Pan-European Study Group. Natalizumab for
active Crohn's disease. N Engl J Med. 348:24–32. 2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Tuloup-Minguez V, Hamaï A, Greffard A,
Nicolas V, Codogno P and Botti J: Autophagy modulates cell
migration and β1 integrin membrane recycling. Cell Cycle.
12:3317–3328. 2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lobert VH, Brech A, Pedersen NM, Wesche J,
Oppelt A, Malerød L and Stenmark H: Ubiquitination of alpha 5 beta
1 integrin controls fibroblast migration through lysosomal
degradation of fibronectin-integrin complexes. Dev Cell.
19:148–159. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wang L, Fortney JE and Gibson LF: Stromal
cell protection of B-lineage acute lymphoblastic leukemic cells
during chemotherapy requires active Akt. Leuk Res. 28:733–742.
2004.PubMed/NCBI View Article : Google Scholar
|
|
43
|
van Wetering S, van den Berk N, van Buul
JD, Mul FP, Lommerse I, Mous R, ten Klooster JP, Zwaginga JJ and
Hordijk PL: VCAM-1-mediated Rac signaling controls endothelial
cell-cell contacts and leukocyte transmigration. Am J Physiol Cell
Physiol. 285:C343–C352. 2003.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chen Q and Massagué J: Molecular pathways:
VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer
Res. 18:5520–5525. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ma YR and Ma YH: MIP-1α enhances Jurkat
cell transendothelial migration by up-regulating endothelial
adhesion molecules VCAM-1 and ICAM-1. Leuk Res. 38:1327–1331.
2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kim TK, Park CS, Na HJ, Lee K, Yoon A,
Chung J and Lee S: Ig-like domain 6 of VCAM-1 is a potential
therapeutic target in TNFα-induced angiogenesis. Exp Mol Med.
49(e294)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Layani-Bazar A, Skornick I, Berrebi A,
Pauker MH, Noy E, Silberman A, Albeck M, Longo DL, Kalechman Y and
Sredni B: Redox modulation of adjacent thiols in VLA-4 by AS101
converts myeloid leukemia cells from a drug-resistant to
drug-sensitive state. Cancer Res. 74:3092–3103. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Karpova D, Rettig MP, Ritchey J, Cancilla
D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J,
et al: Targeting VLA4 integrin and CXCR2 mobilizes serially
repopulating hematopoietic stem cells. J Clin Invest.
129:2745–2759. 2019.PubMed/NCBI View Article : Google Scholar
|
